Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms RO-7428731, RO7428731 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 1 | US | 05 Apr 2022 | |
Glioblastoma | Phase 1 | AU | 05 Apr 2022 | |
Glioblastoma | Phase 1 | CA | 05 Apr 2022 | |
Glioblastoma | Phase 1 | DK | 05 Apr 2022 | |
Glioblastoma | Phase 1 | DE | 05 Apr 2022 | |
Glioblastoma | Phase 1 | NL | 05 Apr 2022 | |
Glioblastoma | Phase 1 | ES | 05 Apr 2022 |